LAVAL,
QC, and CAMBRIDGE,
England, May 9, 2022 /CNW/ - Liminal BioSciences
Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a
clinical-stage biopharmaceutical company, announced that
Bruce Pritchard, Chief Executive
Officer at Liminal BioSciences is scheduled to present a company
overview at the following upcoming investor conferences:
- H.C. Wainwright Global Investment Conference on Tuesday 24th
May at 2:30-3:00 PM (EDT).
- Jefferies Healthcare Conference on Thursday 9th June at
2:00-2:30PM (EDT).
The presentations will be available on Liminal BioSciences'
website at https://investors.liminalbiosciences.com/Webcasts. An
archived replay of the webcast will be available on the Company's
website for at least 7 days after the live event concludes.
About Liminal BioSciences
Inc.
Liminal BioSciences is a clinical stage biopharmaceutical
company focused on developing distinctive novel small molecule
therapeutics for inflammatory, fibrotic, and metabolic diseases
using our drug discovery platform and a data driven approach. The
Company's lead small molecule product candidate, fezagepras, has
completed a Phase 1 multiple ascending dose clinical trial and the
Company anticipates conducting a Phase 1a single ascending dose
clinical trial to provide comparative data to support its
development plan. In addition, the Company is also currently
developing a selective GPR84 antagonist candidate and a selective
OXER1 antagonist candidate. Our GPR84 and OXER1 antagonist programs
are currently at the preclinical stage.
Liminal BioSciences has active business operations in
Canada and the United Kingdom.
Forward Looking
Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Some of the forward-looking statements can be identified
by the use of forward-looking words. Statements that are not
historical in nature, including the words "anticipate," "expect,"
"suggest," "plan," "believe," "intend," "estimate," "target,"
"project," "should," "could," "would," "may," "will," "forecast"
and other similar expressions are intended to identify
forward-looking statements. These statements include those related
to Liminal BioSciences' objectives, strategies and businesses that
involve risks and uncertainties. Forward–looking information
includes statements concerning, among other things: advancement of
Liminal Biosciences' product candidates, the outcome of anticipated
clinical trials; the analysis of our clinical trial data; the
potential development of Liminal Biosciences' R&D programs; the
properties of our drug candidates; the timing of initiation or
nature of preclinical and clinical trials and potential therapeutic
areas.
These statements are "forward-looking" because they are based on
our current expectations about the markets we operate in and on
various estimates and assumptions. Actual events or results may
differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our
estimates or assumptions turn out to be inaccurate. Among the
factors that could cause actual results to differ materially from
those described or projected herein include, but are not limited
to, risks associated with: the Company's ability to develop,
manufacture, and successfully commercialize product candidates, if
ever; the impact of the COVID-19 pandemic on the Company's
workforce, business operations, clinical development, regulatory
activities and financial and other corporate impacts; the
availability of funds and resources to pursue R&D projects,
clinical development, manufacturing operations or commercialization
activities; the successful and timely initiation or completion of
clinical trials; the ability to take advantage of financing
opportunities or business opportunities in the pharmaceutical
industry; the Company's ability to resolve the Nasdaq listing
deficiency and regain compliance with the Nasdaq Listing Rules;
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals; and
general changes in economic conditions. You will find a more
detailed assessment of these risks, uncertainties and other risks
that could cause actual events or results to materially differ from
our current expectations in the filings and reports the Company
makes with the U.S. Securities and Exchange Commission and Canadian
Securities Administrators, including in the Annual Report on Form
20-F for the year ended December 31,
2021, as well as other filings and reports Liminal
Biosciences' may make from time to time. Such risks may be
amplified by the ongoing COVID-19 pandemic and any related impacts
on Liminal BioSciences' business and the global economy. As a
result, we cannot guarantee that any given forward-looking
statement will materialize. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements and estimates, which speak only as of the date hereof.
We assume no obligation to update any forward-looking statement
contained in this press release even if new information becomes
available, as a result of future events or for any other reason,
unless required by applicable securities laws and regulations.
View original
content:https://www.prnewswire.com/news-releases/liminal-biosciences-to-present-at-upcoming-investor-conferences-301542158.html
SOURCE Liminal BioSciences Inc.